ASTELLAS PHARMA
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
A Study Evaluating Safety and Tolerability of YM150 Compared to Warfarin in Subjects With Atrial Fibrillation
- First Posted Date
- 2009-07-14
- Last Posted Date
- 2011-01-20
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 1280
- Registration Number
- NCT00938730
Prevention of Recurrence of Venous Thromboembolism in Patients With a History of Venous Thromboembolism
- First Posted Date
- 2009-07-13
- Last Posted Date
- 2011-01-06
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 87
- Registration Number
- NCT00937820
Prevention of Venous Thromboembolism in Subjects Undergoing Hip Fracture Surgery or Surgery in the Lower Extremities
- First Posted Date
- 2009-07-13
- Last Posted Date
- 2010-06-16
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 101
- Registration Number
- NCT00937911
Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts
Phase 3
Completed
- Conditions
- Kidney Transplantation
- Interventions
- Drug: tacrolimusBiological: SimulectDrug: CellceptDrug: CorticosteroidsDrug: RamiprilDrug: Irbesartan
- First Posted Date
- 2009-07-07
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 281
- Registration Number
- NCT00933231
- Locations
- 🇨🇦
Site CA133 Foothills Medical Centre, Calgary, Alberta, Canada
🇨🇦Site CA54 University of Alberta Hospital, Edmonton, Alberta, Canada
🇨🇦Site CA27 London Health Sciences Centre, London, Ontario, Canada
A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma
Phase 3
Completed
- Conditions
- Adrenocortical Carcinoma
- Interventions
- Drug: OSI-906Other: Placebo
- First Posted Date
- 2009-06-19
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 139
- Registration Number
- NCT00924989
- Locations
- 🇺🇸
Mary Crowley Cancer Research Center, Dallas, Texas, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
🇨🇦Centre hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada
Effect of Food Intake on Pharmacokinetic Profiles of Z-338
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Z-338
- First Posted Date
- 2009-06-16
- Last Posted Date
- 2009-07-20
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 30
- Registration Number
- NCT00920998
A Preliminary Study to Explore Clinical Endpoints in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome
- First Posted Date
- 2009-06-11
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 98
- Registration Number
- NCT00918411
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery
Phase 2
Completed
- Conditions
- Venous Thromboembolism
- Interventions
- First Posted Date
- 2009-06-10
- Last Posted Date
- 2010-06-16
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 369
- Registration Number
- NCT00917254
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
- First Posted Date
- 2009-06-03
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 2030
- Registration Number
- NCT00912964
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery
Phase 2
Completed
- Conditions
- Venous Thromboembolism
- Interventions
- First Posted Date
- 2009-06-03
- Last Posted Date
- 2010-06-09
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 610
- Registration Number
- NCT00913120
© Copyright 2025. All Rights Reserved by MedPath